Redhill Biopharma Stock Net Asset
| RDHL Stock | USD 6.74 0.34 5.31% |
Redhill Biopharma fundamentals help investors to digest information that contributes to Redhill Biopharma's financial success or failures. It also enables traders to predict the movement of Redhill Stock. The fundamental analysis module provides a way to measure Redhill Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Redhill Biopharma stock.
Redhill | Net Asset |
Redhill Biopharma Company Net Asset Analysis
Redhill Biopharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Redhill Biopharma Net Asset | 23.05 M |
Most of Redhill Biopharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Redhill Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Redhill Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Redhill Biopharma is extremely important. It helps to project a fair market value of Redhill Stock properly, considering its historical fundamentals such as Net Asset. Since Redhill Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Redhill Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Redhill Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Redhill Total Assets
Total Assets |
|
Based on the recorded statements, Redhill Biopharma has a Net Asset of 23.05 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Redhill Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Redhill Biopharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Redhill Biopharma could also be used in its relative valuation, which is a method of valuing Redhill Biopharma by comparing valuation metrics of similar companies.Redhill Biopharma is currently under evaluation in net asset category among its peers.
Redhill Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Redhill Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Redhill Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
Redhill Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Redhill Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Redhill Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Redhill Biopharma's value.| Shares | Wells Fargo & Co | 2024-06-30 | 23.0 | Jpmorgan Chase & Co | 2024-06-30 | 11.0 | Ifp Advisors, Llc | 2024-06-30 | 7.0 | We Are One Seven, Llc | 2024-09-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | Aspire Private Capital, Llc | 2024-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Gagnon Securities Llc | 2024-09-30 | 0.0 | Sabby Management Llc | 2024-06-30 | 1.3 M | Ubs Group Ag | 2024-06-30 | 142.4 K | Citadel Advisors Llc | 2024-06-30 | 108.6 K |
Redhill Fundamentals
| Return On Equity | -17.09 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (3.28) % | ||||
| Current Valuation | 1.91 M | ||||
| Shares Outstanding | 1.28 M | ||||
| Shares Owned By Institutions | 5.90 % | ||||
| Number Of Shares Shorted | 1.56 K | ||||
| Price To Earning | (3.67) X | ||||
| Price To Book | 141.49 X | ||||
| Price To Sales | 2.33 X | ||||
| Revenue | 6.51 M | ||||
| Gross Profit | 45.25 M | ||||
| EBITDA | 26.27 M | ||||
| Net Income | 23.92 M | ||||
| Cash And Equivalents | 28.86 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 1.17 M | ||||
| Debt To Equity | 9.89 % | ||||
| Current Ratio | 0.98 X | ||||
| Book Value Per Share | 0.05 X | ||||
| Cash Flow From Operations | (35.82 M) | ||||
| Short Ratio | 0.09 X | ||||
| Earnings Per Share | (302.63) X | ||||
| Target Price | 19000.0 | ||||
| Number Of Employees | 53 | ||||
| Beta | 3.67 | ||||
| Market Capitalization | 8.63 M | ||||
| Total Asset | 23.05 M | ||||
| Retained Earnings | (407.74 M) | ||||
| Working Capital | (3.1 M) | ||||
| Current Asset | 60.51 M | ||||
| Current Liabilities | 5.51 M | ||||
| Net Asset | 23.05 M |
About Redhill Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Redhill Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Redhill Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Redhill Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Redhill Biopharma Piotroski F Score and Redhill Biopharma Altman Z Score analysis. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share 4.733 | Quarterly Revenue Growth (0.28) | Return On Assets (0.45) | Return On Equity (17.09) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.